Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 101 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Transplant; Failure, Liver Clear all
Completed No phase listed Observational

Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival

NCT00531921
View directory record Official record
Conditions
Heart Transplantation, Kidney Transplantation, Liver Transplantation, Lung Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 70 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Ithaca, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 2, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

RESTORE Declined Livers Study

NCT04483102
View directory record Official record
Conditions
Liver Diseases, Surgery, Transplant; Failure, Liver
Interventions
Declined liver in Normothermic Machine Perfusion (NMP), Standard cold preservation of liver
Device · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 2, 2026, 4:58 PM EDT
Recruiting Not applicable Interventional

Abdominal Wall Transplant

NCT03310905
View directory record Official record
Conditions
Transplant;Failure,Kidney, Transplant; Failure, Liver, Transplant; Failure, Bowel, Abdominal Wall Defect, Abdominal Wall Fistula, Abdominal Wall Hernia, Abdominal Wall Injury
Interventions
Abdominal Wall Transplant with another solid organ transplant, Abdominal Wall Transplant alone
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 2, 2026, 4:58 PM EDT
Terminated Not applicable Interventional Results available

Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline

NCT02123576
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Pentoxyfylline, Placebo, AMO Therapy
Drug
Lead sponsor
Patrick Northup, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 2, 2026, 4:58 PM EDT
Completed No phase listed Observational

Hemodynamic Measurements During Liver Transplantation

NCT00682110
View directory record Official record
Conditions
Liver Transplantation
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Oct 2, 2026, 4:58 PM EDT
Completed No phase listed Observational

Identifying Perceived Barriers and Facilitators Toward a Liver Transplantation Prehabilitation

NCT04854564
View directory record Official record
Conditions
Liver Transplant; Complications
Interventions
Prehabilitation intervention, Caregiver intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 74 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 2, 2026, 4:58 PM EDT
Completed No phase listed Observational

Myfortic, Prograf, and Corticosteroids in de Novo Liver Transplantation

NCT01467011
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Enteric-coated Mycophenolate Sodium
Drug
Lead sponsor
R. Mark Ghobrial, MD
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 2, 2026, 4:58 PM EDT
Terminated Phase 3 Interventional Results available

Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function

NCT04258423
View directory record Official record
Conditions
Kidney Failure
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 2, 2026, 4:58 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues

NCT01757730
View directory record Official record
Conditions
Heart Failure, Liver Fibrosis, Cardiac Transplant Rejection, Aortic Aneurysms
Interventions
Not listed
Lead sponsor
Arunark Kolipaka
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 2, 2026, 4:58 PM EDT
Recruiting Not applicable Interventional

Adverse Outcomes and Mortality in Liver Transplant

NCT05477277
View directory record Official record
Conditions
End Stage Liver DIsease, Sarcopenia, Sarcopenic Obesity, Cirrhosis
Interventions
MAsS
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 2, 2026, 4:58 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

NCT03394365
View directory record Official record
Conditions
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Interventions
tabelecleucel
Biological
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
Not listed
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
40
States / cities
Duarte, California • La Jolla, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 2, 2026, 4:58 PM EDT
Withdrawn Phase 4 Interventional

Parenteral Ascorbic Acid Repletion in TransplantatIon

NCT04756063
View directory record Official record
Conditions
Liver Transplant Failure and Rejection
Interventions
Ascorbic acid, Placebo
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 2, 2026, 4:58 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

TLI- and ATG-Enabled Minimization Protocol in Liver Transplantation

NCT07634562
View directory record Official record
Conditions
Liver Failure
Interventions
Anti-Thymocyte Globulin, ATG (Rabbit), Total lymphoid irradiation
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 2, 2026, 4:58 PM EDT
Active, not recruiting No phase listed Observational

Disparities Among Liver Transplant Patients

NCT05981196
View directory record Official record
Conditions
End Stage Liver DIsease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Timeline
2023 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 2, 2026, 4:58 PM EDT
Completed Not applicable Interventional

Prehabilitation Intervention to Maximize Early Recovery (PRIMER) in Liver Transplantation

NCT03584646
View directory record Official record
Conditions
Liver Diseases, End Stage Liver Disease, Frailty
Interventions
Nokia GO Wearable StepTracker, Medication Reminder, Weekly Check-in appointment with study team or provider
Device · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 2, 2026, 4:58 PM EDT
Completed No phase listed Observational

Assessment of Endothelial Function, Apolipoproteins and Adiponectin

NCT01300390
View directory record Official record
Conditions
Cirrhosis
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 2, 2026, 4:58 PM EDT
Withdrawn No phase listed Observational

Optimal A1c Control in Post Liver or Combined Liver and Kidney Transplant Recipients Who Have Diabetes Mellitus

NCT04216303
View directory record Official record
Conditions
Diabetes, Liver Transplant; Complications, Kidney Transplant Failure
Interventions
hemoglobin A1c
Diagnostic Test
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 2, 2026, 4:58 PM EDT
Completed Phase 1 Interventional

Oral Fecal Transplant in Cirrhosis

NCT03152188
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
FMT, Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 2, 2026, 4:58 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients

NCT06153641
View directory record Official record
Conditions
Liver Transplant Rejection, Liver Transplant Failure and Rejection
Interventions
N/A-Observational Study
Other
Lead sponsor
St. Louis University
Other
Eligibility
1 Year and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 2, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant

NCT00135694
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure
Interventions
calcineurin inhibitor-based immunosuppression, liver transplant, corticosteroids, immunosuppression withdrawal
Drug · Procedure · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 2, 2026, 4:58 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Hepatitis C Transplant Collaborative

NCT04493385
View directory record Official record
Conditions
Transplant; Failure, Heart, Hepatitis C
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 2, 2026, 4:58 PM EDT
Withdrawn Phase 4 Interventional

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

NCT04614142
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Hepatitis c
Interventions
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
34 Years to 44 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 2, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients

NCT00772148
View directory record Official record
Conditions
Liver Failure
Interventions
LCP -Tacro, Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Oct 2, 2026, 4:58 PM EDT